T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics

Abiko, 2015, IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer, British Journal of Cancer, 112, 1501, 10.1038/bjc.2015.101 Adams, 2001, High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules, Cancer Research, 61, 4750 Ahmed, 2015, Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody, OncoImmunology, 4, 10.4161/2162402X.2014.989776 Arndt, 2014, Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system, Leukemia, 28, 59, 10.1038/leu.2013.243 Asano, 2014, Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics, MAbs, 6, 1243, 10.4161/mabs.29445 Asano, 2007, Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells, Journal of Biological Chemistry, 282, 27659, 10.1074/jbc.M704719200 Bacac, 2016, A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors, Clinical Cancer Research, 22, 3286, 10.1158/1078-0432.CCR-15-1696 Bakker, 2014, Bispecific IgG antibodies as T cell engagers Bargou, 2008, Tumor regression in cancer patients by very low doses of a T cell–engaging antibody, Science, 321, 974, 10.1126/science.1158545 Becht, 2016, Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers, Advances in Immunology, 130, 95, 10.1016/bs.ai.2015.12.002 Bellone, 2013, Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes, Frontiers in Oncology, 3, 231, 10.3389/fonc.2013.00231 Blanco, 2003, Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells, The Journal of Immunology, 171, 1070, 10.4049/jimmunol.171.2.1070 Blanco-Toribio, 2013, Generation and characterization of monospecific and bispecific hexavalent trimerbodies, MAbs, 5, 70, 10.4161/mabs.22698 Blank-Voorthuis, 1993, Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3, The Journal of Immunology, 151, 2904, 10.4049/jimmunol.151.6.2904 Bluemel, 2010, Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen, Cancer Immunology, Immunotherapy, 59, 1197, 10.1007/s00262-010-0844-y Bongini, 2004, Freezing immunoglobulins to see them move, Proceedings of the National Academy of Sciences of the United States of America, 101, 6466, 10.1073/pnas.0400119101 Bonino, 1995, Bispecific monoclonal antibody anti-CD3 X anti-tenascin: An immunotherapeutic agent for human glioma, International Journal of Cancer, 61, 509, 10.1002/ijc.2910610414 Bortoletto, 2002, Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells, European Journal of Immunology, 32, 3102, 10.1002/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C Brack, 2014, A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action, Molecular Cancer Therapeutics, 13, 2030, 10.1158/1535-7163.MCT-14-0046-T Brinkmann, 2017, The making of bispecific antibodies, MAbs, 9, 182, 10.1080/19420862.2016.1268307 Brischwein, 2006, MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors, Molecular Immunology, 43, 1129, 10.1016/j.molimm.2005.07.034 Bühler, 2008, A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells, Cancer Immunology, Immunotherapy, 57, 43, 10.1007/s00262-007-0348-6 Calcinotto, 2012, Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy, The Journal of Immunology, 188, 2687, 10.4049/jimmunol.1101877 Cao, 2015, Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers, Angewandte Chemie, 127, 7128, 10.1002/ange.201500799 Chamow, 1994, A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells, The Journal of Immunology, 153, 4268, 10.4049/jimmunol.153.9.4268 Chan, 2006, Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study, Clinical Cancer Research, 12, 1859, 10.1158/1078-0432.CCR-05-2019 Chelius, 2010, Structural and functional characterization of the trifunctional antibody catumaxomab, MAbs, 2, 309, 10.4161/mabs.2.3.11791 Cheng, 2015, Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy, International Journal of Cancer, 136, 476, 10.1002/ijc.29007 Chichili, 2015, A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates, Science Translational Medicine, 7, 10.1126/scitranslmed.aaa5693 Choi, 2013, Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma, Proceedings of the National Academy of Sciences of the United States of America, 110, 270, 10.1073/pnas.1219817110 Chu, 2014, Immunotherapy with long-lived anti-CD38×anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: A potential therapy for multiple myeloma, Blood, 124, 4727, 10.1182/blood.V124.21.4727.4727 Chu, 2014, Immunotherapy with long-lived anti-CD123×anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: A potential therapy for acute myelogenous leukemia, Blood, 124, 2316, 10.1182/blood.V124.21.2316.2316 Cochlovius, 2000, Treatment of human B cell lymphoma xenografts with a CD3×CD19 diabody and T cells, The Journal of Immunology, 165, 888, 10.4049/jimmunol.165.2.888 Cochlovius, 2000, Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, Tetravalent CD3×CD19 tandem diabody, and CD28 costimulation, Cancer Research, 60, 4336 Croset, 2014, 139 GBR1302: a BEAT&#xae; bispecific antibody for the treatment of HER2 positive cancers, European Journal of Cancer, 50, 48, 10.1016/S0959-8049(14)70265-5 Cui, 2012, Chemically programmed bispecific antibodies that recruit and activate T cells, Journal of Biological Chemistry, 287, 28206, 10.1074/jbc.M112.384594 Daniel, 1998, Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: Costimulation via CD28 prevents “veto” apoptosis of antibody-targeted cytotoxic T cells, Blood, 92, 4750, 10.1182/blood.V92.12.4750 Dao, 2015, Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1, Nature Biotechnology, 33, 1079, 10.1038/nbt.3349 Dettmar, 2012, Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM×anti-CD3) treatment in vivo, Clinical and Translational Oncology, 14, 376, 10.1007/s12094-012-0811-5 Dorken, 2006, CD 19×CD3 specific polypeptides and uses thereof Dreier, 2003, T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, The Journal of Immunology, 170, 4397, 10.4049/jimmunol.170.8.4397 Dreier, 2002, Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody, International Journal of Cancer, 100, 690, 10.1002/ijc.10557 Fan, 2015, Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3×anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells, Journal of Hematology & Oncology, 8, 108, 10.1186/s13045-015-0205-6 Faroudi, 2003, Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold, Proceedings of the National Academy of Sciences, 100, 14145, 10.1073/pnas.2334336100 Feldmann, 2012, Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8⁺ and CD4⁺ T cells, The Journal of Immunology, 189, 3249, 10.4049/jimmunol.1200341 Feldmann, 2011, Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats, The Prostate, 71, 998, 10.1002/pros.21315 Ferrini, 1993, Targeting of T lymphocytes against egf-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for T-cell activation, International Journal of Cancer, 55, 931, 10.1002/ijc.2910550610 Feucht, 2016, T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts, Oncotarget, 7, 76902, 10.18632/oncotarget.12357 Fisher, 2014, The two faces of IL-6 in the tumor microenvironment, Seminars in Immunology, 26, 38, 10.1016/j.smim.2014.01.008 Friedrich, 2014, Preclinical characterization of AMG 330, a CD3/CD33-Bispecific T-cell–engaging antibody with potential for treatment of acute myelogenous leukemia, Molecular Cancer Therapeutics, 13, 1549, 10.1158/1535-7163.MCT-13-0956 Friedrich, 2012, Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens, Molecular Cancer Therapeutics, 11, 2664, 10.1158/1535-7163.MCT-12-0042 Gajewski, 2013, Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment, Current Opinion in Immunology, 25, 268, 10.1016/j.coi.2013.02.009 Gall, 2005, T cells armed with anti-CD3×anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro, Experimental Hematology, 33, 452, 10.1016/j.exphem.2005.01.007 Gao, 2004, Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein [times] anti-CD3 diabody, Leukemia, 18, 513, 10.1038/sj.leu.2403267 Gaudet, 2016, Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML), Blood, 128, 2824, 10.1182/blood.V128.22.2824.2824 Gooden, 2011, The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis, British Journal of Cancer, 105, 93, 10.1038/bjc.2011.189 Griffiths, 2010, The immunological synapse: A focal point for endocytosis and exocytosis, The Journal of Cell Biology, 189, 399, 10.1083/jcb.201002027 Haas, 2009, Mode of cytotoxic action of T cell-engaging BiTE antibody MT110, Immunobiology, 214, 441, 10.1016/j.imbio.2008.11.014 Haense, 2016, A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors, BMC Cancer, 16, 420, 10.1186/s12885-016-2449-0 Han, 2014, Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo, International Journal of Oncology, 45, 2446, 10.3892/ijo.2014.2663 Harrington, 2015, The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk, PLoS One, 10, 10.1371/journal.pone.0135945 Hayashi, 2004, A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells, Cancer Immunology, Immunotherapy, 53, 497, 10.1007/s00262-003-0465-9 Heczey, 2014, Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy, Blood, 124, 2824, 10.1182/blood-2013-11-541235 Hernandez-Hoyos, 2016, MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer, Molecular Cancer Therapeutics, 15, 2155, 10.1158/1535-7163.MCT-15-0242 Herrmann, 2010, Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells, PLoS One, 5, 10.1371/journal.pone.0013474 Hettich, 2016, Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing γ-irradiation, Cancer Research, 76, 4673, 10.1158/0008-5472.CAN-15-3451 Hipp, 2017, A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo, Leukemia, 31, 1743, 10.1038/leu.2016.388 Hobbs, 1998, Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, Proceedings of the National Academy of Sciences, 95, 4607, 10.1073/pnas.95.8.4607 Hoffmann, 2005, Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct, International Journal of Cancer, 115, 98, 10.1002/ijc.20908 Hoffmann, 2011, Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy, International Journal of Cancer, 128, 2096, 10.1002/ijc.25556 Hofmeister, 2005, Multispecific deimmunized cd3-binders Holliger, 1999, Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3×anti-CEA bispecific diabodies and B7×anti-CEA bispecific fusion proteins, Cancer Research, 59, 2909 Huang, 2014, CD3-binding molecules capable of binding to human and non-human CD3 Huang, 2013, Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo, Clinical Immunology, 149, 156, 10.1016/j.clim.2013.07.006 Huarte, 2009, Ex vivo expansion of tumor specific lymphocytes with, Cancer Letters, 285, 80, 10.1016/j.canlet.2009.05.003 Ishiguro, 2016, Abstract DDT01-05: First-in-class T cell-redirecting bispecific antibody targeting glypican-3: A highly tumor-selective antigen, Cancer Research, 76, 10.1158/1538-7445.AM2016-DDT01-05 Iyoda, 2010, Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation, International Immunology, 22, 905, 10.1093/intimm/dxq444 Junttila, 2014, Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells, Cancer Research, 74, 5561, 10.1158/0008-5472.CAN-13-3622-T Kim, 2012, Synthesis of bispecific antibodies using genetically encoded unnatural amino acids, Journal of the American Chemical Society, 134, 9918, 10.1021/ja303904e Kipriyanov, 1999, Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics1, Journal of Molecular Biology, 293, 41, 10.1006/jmbi.1999.3156 Kischel, 2009, Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110, Cancer Research, 69, 3252 Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Kontermann, 2015, Bispecific antibodies, Drug Discovery Today, 20, 838, 10.1016/j.drudis.2015.02.008 Kufer, 2009, Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders Kuhn, 2016, Therapeutic anti-CD3 monoclonal antibodies: From bench to bedside, Immunotherapy, 8, 889, 10.2217/imt-2016-0049 Kuo, 2012, Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells, Protein Engineering, Design and Selection, 25, 561, 10.1093/protein/gzs040 Landskron, 2014, Chronic inflammation and cytokines in the tumor microenvironment, Journal of Immunology Research, 2014, 19, 10.1155/2014/149185 Laszlo, 2015, T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330, Blood Cancer Journal, 5, 10.1038/bcj.2015.68 Lee, 2017, Abstract 3633: Anti-SSTR2×anti-CD3 bispecific antibody induces potent killing of human tumor cells <em>in vitro</em> and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors, Cancer Research, 77, 3633, 10.1158/1538-7445.AM2017-3633 Leong, 2017, An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia, Blood, 129, 609, 10.1182/blood-2016-08-735365 Lewis, 2014, Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface, Nature Biotechnology, 32, 191, 10.1038/nbt.2797 Li, 2017, Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing, Cancer Cell, 31, 383, 10.1016/j.ccell.2017.02.001 Liddy, 2012, Monoclonal TCR-redirected tumor cell killing, Nature Medicine, 18, 980, 10.1038/nm.2764 Liu, 2016, MGD011, A CD19×CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies, Clinical Cancer Research, 23, 1506, 10.1158/1078-0432.CCR-16-0666 Liu, 2017, Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer, Clinical Cancer Research, 23, 478, 10.1158/1078-0432.CCR-16-1203 Liu, 2009, Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli, Cancer Immunology, Immunotherapy, 58, 1761, 10.1007/s00262-009-0684-9 Liu, 2014, Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands, Bioconjugate Chemistry, 25, 1511, 10.1021/bc5002455 Löffler, 2000, A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes, Blood, 95, 2098, 10.1182/blood.V95.6.2098 Lopez-Albaitero, 2017, Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody, OncoImmunology, 6, 10.1080/2162402X.2016.1267891 Lu, 2016, Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma, Biochemical and Biophysical Research Communications, 473, 808, 10.1016/j.bbrc.2016.03.124 Luiten, 1996, Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma, British Journal of Cancer, 74, 735, 10.1038/bjc.1996.430 Lum, 2012, Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3×anti-CMV bispecific antibody, Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 18, 1012, 10.1016/j.bbmt.2012.01.022 Lyubchenko, 2001, Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing, Immunity, 15, 847, 10.1016/S1074-7613(01)00233-3 Mack, 1997, Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity, The Journal of Immunology, 158, 3965, 10.4049/jimmunol.158.8.3965 Matsuzaki, 2015, Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses, Scientific Reports, 5, 14896, 10.1038/srep14896 Mau-Sørensen, 2015, A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3, Cancer Chemotherapy and Pharmacology, 75, 1065, 10.1007/s00280-015-2728-5 McCormack, 2013, Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors, Cancer Immunology, Immunotherapy, 62, 773, 10.1007/s00262-012-1384-4 Mezzanzanica, 1991, Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)₂ antibody prolong host survival in a murine xenograft model, Cancer Research, 51, 5716 Mølhøj, 2007, CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis, Molecular Immunology, 44, 1935, 10.1016/j.molimm.2006.09.032 Moore, 2014, Abstract 669: Development of MGD007, a gpA33×CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer, Cancer Research, 74, 669, 10.1158/1538-7445.AM2014-669 Moore, 2011, A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens, MAbs, 3, 546, 10.4161/mabs.3.6.18123 Moore, 2015, Tuning T cell affinity improves efficacy and safety of anti-CD38×anti-CD3 bispecific antibodies in monkeys - A potential therapy for multiple myeloma, Blood, 126, 1798, 10.1182/blood.V126.23.1798.1798 Moore, 2011, Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma, Blood, 117, 4542, 10.1182/blood-2010-09-306449 Motz, 2011, The parallel lives of angiogenesis and immunosuppression: Cancer and other tales, Nature Reviews. Immunology, 11, 702, 10.1038/nri3064 Negri, 1995, In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody, British Journal of Cancer, 72, 928, 10.1038/bjc.1995.435 Nguyen, 2016, Naïve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment, Scientific Reports, 6, 28208, 10.1038/srep28208 Nisonoff, 1961, Recombination of a mixture of univalent antibody fragments of different specificity, Archives of Biochemistry and Biophysics, 460, 10.1016/0003-9861(61)90296-X Nisonoff, 1960, Properties of the major component of a peptic digest of rabbit antibody, Science, 132, 1770, 10.1126/science.132.3441.1770 Nolz, 2015, Molecular mechanisms of CD8+ T cell trafficking and localization, Cellular and Molecular Life Sciences, 72, 2461, 10.1007/s00018-015-1835-0 Oberst, 2014, CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas, MAbs, 6, 1571, 10.4161/19420862.2014.975660 Oda, 2006, Regional and segmental flexibility of antibodies in interaction with antigens of different size, FEBS Journal, 273, 1476, 10.1111/j.1742-4658.2006.05168.x Oelkrug, 2014, Enhancement of T cell recruitment and infiltration into tumours, Clinical and Experimental Immunology, 178, 1, 10.1111/cei.12382 Offner, 2006, Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells, Molecular Immunology, 43, 763, 10.1016/j.molimm.2005.03.007 Osada, 2015, CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1, Cancer Immunology, Immunotherapy, 64, 677, 10.1007/s00262-015-1671-y Oshimi, 1991, Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab′ antibody cross-linked to anti-CD10 Fab′ antibody, Blood, 77, 1044, 10.1182/blood.V77.5.1044.1044 Pegu, 2015, Activation and lysis of human CD4 cells latently infected with HIV-1, Nature Communications, 6, 8447, 10.1038/ncomms9447 Perez, 1985, Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody, Nature, 316, 354, 10.1038/316354a0 Petrovas, 2017, Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies, Science Translational Medicine, 9 Pfosser, 1999, Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A pre-clinical study, International Journal of Cancer, 80, 612, 10.1002/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K Plückthun, 1997, New protein engineering approaches to multivalent and bispecific antibody fragments, Immunotechnology, 3, 83, 10.1016/S1380-2933(97)00067-5 Pohl, 1993, CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma, International Journal of Cancer, 54, 820, 10.1002/ijc.2910540517 Purbhoo, 2004, T cell killing does not require the formation of a stable mature immunological synapse, Nature Immunology, 5, 524, 10.1038/ni1058 Quezada, 2010, Tumor-reactive CD4⁺ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, The Journal of Experimental Medicine, 207, 637, 10.1084/jem.20091918 Ramadoss, 2015, An anti-B cell maturation antigen bispecific antibody for multiple myeloma, Journal of the American Chemical Society, 137, 5288, 10.1021/jacs.5b01876 Ren-Heidenreich, 2004, Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model, Cancer, 100, 1095, 10.1002/cncr.20060 Renner, 1995, Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies, Journal of Hematotherapy, 4, 447, 10.1089/scd.1.1995.4.447 Restifo, 2012, Adoptive immunotherapy for cancer: harnessing the T cell response, Nature Reviews. Immunology, 12, 269, 10.1038/nri3191 Rettinger, 2012, Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models, Frontiers in Oncology, 2, 32, 10.3389/fonc.2012.00032 Reusch, 2015, A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells, MAbs, 7, 584, 10.1080/19420862.2015.1029216 Reusch, 2016, Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia, Clinical Cancer Research, 22, 5829, 10.1158/1078-0432.CCR-16-0350 Reusch, 2006, Anti-CD3×anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers <em>in vitro</em> and in an animal model, Clinical Cancer Research, 12, 183, 10.1158/1078-0432.CCR-05-1855 Riethmüller, 2012, Symmetry breaking: bispecific antibodies, the beginnings, and 50years on, Cancer Immunity, 12, 12 Root, 2016, Development of PF-06671008, a highly potent anti-P-cadherin/Anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer, Antibodies, 5, 6, 10.3390/antib5010006 Rossi, 2014, Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α, Molecular Cancer Therapeutics, 13, 2341, 10.1158/1535-7163.MCT-14-0345 Rossi, 2014, A new class of bispecific antibodies to redirect T cells for cancer immunotherapy, MAbs, 6, 381, 10.4161/mabs.27385 Ruf, 2004, Two new trifunctional antibodies for the therapy of human malignant melanoma, International Journal of Cancer, 108, 725, 10.1002/ijc.11630 Salnikov, 2009, Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma, Journal of Cellular and Molecular Medicine, 13, 4023, 10.1111/j.1582-4934.2009.00723.x Scheffold, 2002, Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab′)₂HER2xCD3, Cancer Research, 62, 5785 Sebastian, 2007, Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM×anti-CD3): a phase I study, Cancer Immunology, Immunotherapy, 56, 1637, 10.1007/s00262-007-0310-7 Seckinger, 2017, Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment, Cancer Cell, 31, 396, 10.1016/j.ccell.2017.02.002 Sen, 2001, Use of anti-CD3×anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells Toward HER2/neu+ tumors, Journal of Hematotherapy & Stem Cell Research, 10, 247, 10.1089/15258160151134944 Shalaby, 1992, Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene, The Journal of Experimental Medicine, 175, 217, 10.1084/jem.175.1.217 Shen, 1994, Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing, The Journal of Immunology, 152, 2368, 10.4049/jimmunol.152.5.2368 Siddiqui, 2016, Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient, Journal for Immunotherapy of Cancer, 4, 21, 10.1186/s40425-016-0125-1 Smith, 2015, Ex vivo expansion of human T cells for adoptive immunotherapy using the novel xeno-free CTS immune cell serum replacement, Clinical and Translational Immunology, 4, 10.1038/cti.2014.31 Smith, 2015, A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys, Scientific Reports, 5, 17943, 10.1038/srep17943 Spiess, 2015, Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology, 67, 95, 10.1016/j.molimm.2015.01.003 Spranger, 2016, Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment, International Immunology, 28, 383, 10.1093/intimm/dxw014 Stadler, 2016, Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6, OncoImmunology, 5, 10.1080/2162402X.2015.1091555 Staerz, 1985, Hybrid antibodies can target sites for attack by T cells, Nature, 314, 628, 10.1038/314628a0 Stamova, 2011, Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module, Molecular Immunology, 49, 474, 10.1016/j.molimm.2011.09.019 Stanglmaier, 2008, Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20×anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels, International Journal of Cancer, 123, 1181, 10.1002/ijc.23626 Stel, 2004, The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3, The Journal of Immunology, 173, 6009, 10.4049/jimmunol.173.10.6009 Ströhlein, 2014, Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy, Medical Hypotheses, 82, 295, 10.1016/j.mehy.2013.12.014 Sun, 2015, Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies, Science Translational Medicine, 7, 10.1126/scitranslmed.aaa4802 Sun, 2016, Preclinical characterization of combinability and potential synergy of anti-CD20/CD3 T-cell dependent bispecific antibody with chemotherapy and PD-1/PD-L1 blockade, Blood, 128, 4168, 10.1182/blood.V128.22.4168.4168 Sung, 2015, Dual-affinity re-targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells, The Journal of Clinical Investigation, 125, 4077, 10.1172/JCI82314 Takemura, 2002, A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma, Cancer Immunology, Immunotherapy, 51, 33, 10.1007/s00262-001-0245-3 Taki, 2015, A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy, PLoS One, 10, 10.1371/journal.pone.0144712 Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, Blood, 121, 5154, 10.1182/blood-2013-02-485623 Thiery, 2011, Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells, Nature Immunology, 12, 770, 10.1038/ni.2050 Tita-Nwa, 2007, Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells, Cancer Immunology, Immunotherapy, 56, 1911, 10.1007/s00262-007-0333-0 Torisu-Itakura, 2011, Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells, Journal of Immunotherapy (Hagerstown, Md.: 1997), 34, 597 Traunecker, 1991, Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells, The EMBO Journal, 10, 3655, 10.1002/j.1460-2075.1991.tb04932.x Tsukamoto, 1993, Specific targeting of in vitro-activated human antitumour effector cells using anti-CD3 [times] anti-c-erbB-2 bispecific antibody, Immunology and Cell Biology, 71, 109, 10.1038/icb.1993.11 Valitutti, 2010, The space and time frames of T cell activation at the immunological synapse, FEBS Letters, 584, 4851, 10.1016/j.febslet.2010.10.010 Valitutti, 1995, Serial triggering of many T-cell receptors by a few peptide–MHC complexes, Nature, 375, 148, 10.1038/375148a0 Van Loo, 2015, Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML, Blood, 126, 325, 10.1182/blood.V126.23.325.325 Vidarsson, 2014, IgG subclasses and allotypes: From structure to effector functions, Frontiers in Immunology, 5, 520, 10.3389/fimmu.2014.00520 Wang, 2013, Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody, PLoS One, 8 Watanabe, 2011, In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody, Oncology Reports, 26, 949 WHO, 2014, Proposed international nonproprietary names, 251 Wild, 1999, Tumor therapy with bispecific antibody: The targeting and triggering steps can be separated employing a CD2-based strategy, The Journal of Immunology, 163, 2064, 10.4049/jimmunol.163.4.2064 Wozniak-Knopp, 2010, Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties, Protein Engineering, Design and Selection, 23, 289, 10.1093/protein/gzq005 Wu, 2015, Fab-based bispecific antibody formats with robust biophysical properties and biological activity, MAbs, 7, 470, 10.1080/19420862.2015.1022694 Wu, 2012, CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma, Molecular Cancer Therapeutics, 11, 1809, 10.1158/1535-7163.MCT-11-1014 Wuellner, 2015, Bispecific CD3/HER2 targeting FynomAb induces redirected T cell-mediated cytolysis with high potency and enhanced tumor selectivity, Antibodies, 4, 426, 10.3390/antib4040426 Xiong, 2002, Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20×anti-CD3 bispecific diabody, Cancer Letters, 177, 29, 10.1016/S0304-3835(01)00758-3 Xu, 2015, Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody, Cancer Immunology Research, 3, 266, 10.1158/2326-6066.CIR-14-0230-T Xu, 2015, Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system, MAbs, 7, 231, 10.4161/19420862.2015.989013 Yamamoto, 2012, A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells, Biochemical Journal, 445, 135, 10.1042/BJ20120433 Yoshida, 2003, T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites, Blood, 101, 2300, 10.1182/blood-2002-03-0831 Zeidler, 1999, Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing, The Journal of Immunology, 163, 1246, 10.4049/jimmunol.163.3.1246 Zhang, 2014, An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression, Cancer Immunology, Immunotherapy, 63, 121, 10.1007/s00262-013-1497-4 Zhao, 2015, Targeting CD133high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody, Journal of Immunotherapy, 38, 217, 10.1097/CJI.0000000000000086 Zhou, 2006, Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes, Clinical Cancer Research, 12, 2224, 10.1158/1078-0432.CCR-05-1524 Zhu, 2010, COMBODY: one-domain antibody multimer with improved avidity, Immunology and Cell Biology, 88, 667, 10.1038/icb.2010.21 Zou, 2015, Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma, Cancer Science, 106, 512, 10.1111/cas.12631 Zou, 2016, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations, Science Translational Medicine, 8, 10.1126/scitranslmed.aad7118